Perth , Australia

Institute for Respiratory Health

Recurrence

Cardiovascular Diseases

Cystic Fibrosis

Idiopathic Pulmonary Fibrosis

Chronic Obstructive Pulmonary Disease

Respiratory Tract Infections

Pseudomonas Infections

Lung Diseases

Bronchiolitis Obliterans Syndrome

Obstructive Lung Diseases

Axatilimab

RSP-1502

Bisoprolol

Respirion Pharmaceuticals

Syndax Pharmaceuticals

The George Institute

condition

allSponsorName

DevPro Biopharma

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The study will evaluate the efficacy and safety of axatilimab in participants with IPF.

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Institute for Respiratory Health | Perth , Australia

Site insights

Work at this site?

Active trials

MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Trial sponsors